Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company headquartered in Waltham, Massachusetts, focused on bioprocessing technologies and systems that support the manufacturing of biological drugs. This news page aggregates company announcements, earnings updates, product launches and strategic developments directly related to Repligen’s operations in bioprocessing.
According to its public communications, Repligen serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs), with core focus areas in Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. News items often highlight how these focus areas evolve through new products, partnerships and technology integrations.
Investors and industry followers can use this page to review earnings press releases and related Form 8-K announcements, which cover quarterly financial results, guidance updates and commentary on demand trends across Repligen’s franchises and geographies. The company’s releases also discuss the use of non-GAAP financial measures and provide reconciliations to GAAP results.
Repligen’s news flow additionally includes product and technology updates, such as the launch of new chromatography resins in its proteins portfolio and introductions of equipment in areas like mixing and process analytics. Strategic partnerships, including its collaboration with Novasign to integrate machine learning and modeling workflows into Repligen filtration systems, are another recurring theme.
Governance and leadership developments, such as Board chair transitions and senior finance appointments disclosed via press releases and Form 8-K filings, also appear in the news stream. By checking this page regularly, readers can follow how Repligen describes its progress in bioprocessing technology leadership, digitalization initiatives, and its engagement with the biopharmaceutical and CDMO sectors.
Summary not available.
Summary not available.
Summary not available.
Repligen Corporation (NASDAQ:RGEN) will announce its first quarter 2023 financial results on May 2, 2023, before the market opens. A conference call is scheduled for 8:30 a.m. ET to discuss business updates and financial results for the quarter ending March 31, 2023. Investors can join the call by dialing (844) 274-3999 (U.S.) or (412) 317-5607 (international) without a passcode. A webcast will also be available on the Company’s Investor Relations page. Repligen specializes in bioprocessing technologies for biopharmaceutical manufacturing.
Repligen Corporation (NASDAQ:RGEN) announced its participation in the KeyBanc Life Science and MedTech Investor Forum on March 21-22, 2023. CEO Tony J. Hunt will lead an analyst-led discussion on March 21 at 1:30 p.m. EDT. A live webcast of the presentation will be available on the Company's Investor Relations website and will be accessible for replay after the event. Repligen specializes in bioprocessing technologies, aiming to improve the manufacturing efficiency of biological drugs for biopharmaceutical developers and contract organizations globally. The company operates in various locations, primarily within the U.S., and has a strong presence in multiple European countries.
Repligen Corporation (NASDAQ:RGEN) reported strong financial results for the fourth quarter and full year 2022. Fourth quarter revenue reached $186.8 million, marking 4% organic growth year-over-year, while full-year revenue totaled $801.5 million, a 22% organic growth. The base business demonstrated impressive organic growth of 35% in Q4 and 39% for the year. Despite these achievements, gross profit decreased in Q4 by 9%, impacted by declining COVID-related product revenues and increased costs. Looking ahead, Repligen expects 2023 total revenue between $760-$800 million, anticipating a reduction in COVID-related revenue and gross margin decline to 52.5%-53.5%.
Repligen Corporation (NASDAQ:RGEN) has appointed Martin D. Madaus to its Board of Directors, enhancing its leadership in the bioprocessing sector. Dr. Madaus brings over 25 years of experience, notably transforming Millipore Corporation into a life sciences leader before its acquisition by Merck KGaA. He currently serves on the boards of multiple public and private companies and will leverage his expertise in strategy and commercial operations to support Repligen's growth and innovation. Company leadership expresses confidence in his contributions towards expanding their product portfolio and market presence.
Repligen Corporation (NASDAQ:RGEN) will announce its Q4 and full-year 2022 financial results on February 22, 2023. A press release will precede the market opening, followed by a conference call at 8:30 a.m. EST. This event will discuss updates and financial results for the periods ended December 31, 2022. Investors can access the conference call by dialing (844) 274-3999 domestically or (412) 317-5607 internationally. The event will be archived for later access. Repligen focuses on bioprocessing technologies and operates globally, with key manufacturing sites in the U.S. and Europe.
Repligen Corporation (NASDAQ:RGEN) announced its participation at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. CEO Tony J. Hunt will present on January 10 at 2:15 p.m. PST. The presentation will be available via a live webcast through the Company’s Investor Relations section and can be replayed afterwards for a limited time.
Repligen is a leader in bioprocessing technologies, focusing on improving efficiencies in manufacturing biological drugs and serving biopharmaceutical developers and CDMOs globally.
Repligen Corporation (NASDAQ:RGEN) announced its participation in two prominent investor conferences. The Stifel 2022 Healthcare Conference will take place on November 15-16 in New York, where CFO Jon K. Snodgres will lead a discussion on November 16 at 2:25 p.m. EST. Additionally, the Stephens’ Annual Investment Conference is set for November 15-17 in Nashville, with Snodgres speaking on November 17 at 2:00 p.m. EST. A live webcast will be available on the company’s website and can be replayed for a limited time after the events.